Can VI-RADS/ADC Accurately Stage Bladder Cancer??
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04167631|
Recruitment Status : Active, not recruiting
First Posted : November 19, 2019
Last Update Posted : November 22, 2019
|Condition or disease||Intervention/treatment||Phase|
|MRI Contrast Media Adverse Reaction Bladder Cancer Bladder Disease Bladder Neoplasm Bladder Urothelial Carcinoma Bladder Cancer Stage Diagnoses Disease||Radiation: Multi-parametric MRI||Not Applicable|
Vesical Imaging-Reporting And Data System (VI-RADS) is proposed for predicting muscle invasive bladder cancer (MIBC) using multi-parametric MRI. However, No validation study on VI-RADS has been reported yet. Apparent diffusion coefficient (ADC) values on diffusion-weighted MRI are reportedly significantly lower in MIBC than those in non-MIBC(NMIBC).
We aim to examine the accuracy of VI-RADS for predicting MIBC in final histopathology specimen. To assess whether incorporating ADC into VI-RADS improves the MIBC predictive accuracy of VI-RADS
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Can Vesical Imaging-Reporting And Data System and Apparent Diffusion Coefficient Values (the VI-RADS/ADC) Accurately Predict Non-Muscle Invasive Bladder Cancer|
|Actual Study Start Date :||January 1, 2019|
|Estimated Primary Completion Date :||June 1, 2020|
|Estimated Study Completion Date :||June 1, 2020|
Vesical Imaging-Reporting And Data System (VI-RADS) using multi-parametric MRI.
Radiation: Multi-parametric MRI
Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
Other Name: MP-MRI
- Vesical Imaging-Reporting And Data System (VI-RADS) for discriminating muscle invasive bladder cancer (MIBC) from non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI. [ Time Frame: 18 months ]assessed by final histopathology specimen retrieved by enbloc transurethral resection of bladder tumors (ERBT)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04167631
|Urology and Nephrology Center|
|Mansoura, Aldakahlia, Egypt, 35516|
|Study Chair:||Ahmed Mosbah, MD||Mansoura University|
|Study Director:||Mohammed Aboelghar, MD||Mansoura University|